ClelandJGF. Is aspirin useful in primary prevention?Eur Heart J2013; 34(44): 3412–3418.
2.
ClelandJGF. Aspirin for secondary prevention of atherosclerosis-evidence or dogma?JAMA Cardiol2025; 10(2): 114–116.
3.
ClelandJGFAnzarD. Commentary on Wittes et al: Aspirin for primary prevention of CV events: rationally robust? Statistically significant? Clinically convincing?Clin Trials2025.
4.
WittesJDeMetsDLKimK, et al. Aspirin in primary prevention: undue reliance on an uninformative trial led to misinformed clinical guidelines. Clin Trials2025.
5.
KimKHennekensCHMartinezL, et al. Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit to risk ratio, not age. Fam Med Community Health2021; 9(4): e001475.
6.
McNeilJJNelsonMRWoodsRL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med2018; 379(16): 1519–1528.
7.
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ2002; 324(3729): 71–86.
8.
WeitzJL. Arterial thrombosis: present and future. Circulation2024; 150(12): 903–907.
